Investor FAQs - ArriVent Biopharma

18 Campus Boulevard, Suite 100, Newtown Square, PA 19073

ArriVent is incorporated in Delaware.

ArriVent was founded in 2021.

ArriVent’s initial public offering (IPO) occurred on January 26, 2024.

ArriVent’s shares are traded on the Nasdaq Global Market under the symbol AVBP

ArriVent’s fiscal year ends on December 31.

Computershare

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C

KPMG

The CUSIP for ArriVent is #04272N 102

Shares of ArriVent’s stock can be purchased by contacting a securities broker of your choice.

ArriVent does not currently pay dividends or offer a dividend reinvestment program.

For questions about your stock please contact our transfer agent, Computershare

Quarterly & Annual reports and other investor materials are available in the “Investors” section of ArriVent’s corporate website. Additionally, all SEC filings can also be accessed directly from the SEC at www.sec.gov.

Please click here to be directed to the email alerts page.

For media inquiries, please send an email to info@arrivent.com

For investor inquiries, please send an email to jallaire@lifesciadvisors.com.

Where is ArriVent headquartered?

Where is ArriVent incorporated ?

When was ArriVent founded?

When did ArriVent go public?

Which stock exchange are ArriVent shares traded on and what is the company’s ticker?

When does ArriVent’s fiscal year end?

Who is ArriVent’s transfer agent?

Who is ArriVent’s legal counsel?

Who are ArriVent’s independent registered public account firm?

What is ArriVent’s CUSIP number?

How can I purchase ArriVent shares?

Does ArriVent pay dividends and have a dividend reinvestment program?

Whom do I contact with questions about my stock (transfer stock, change the address on my shareholder account, or replace a lost stock certificate)?

How can I view documents ArriVent has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?

How can I sign up to receive ArriVent press releases and other company information?

Whom should I contact if I am a member of the media?

Whom should I contact if I have additional questions?